
The zzso zzso is widely used for pain related to cancer, but the evidence to support its use in this setting is zzso This study aimed to determine whether zzso is more effective than zzso when used in conjunction with zzso and standard zzso therapy in the management of chronic uncontrolled cancer zzso zzso would be considered of net benefit if it provided clinically relevant improvement in pain with limited breakthrough analgesia and acceptable zzso 

In this zzso zzso zzso randomized, zzso phase III trial, zzso or zzso was delivered zzso over 3 to 5 zzso 

In all, 185 participants were included in the primary zzso There was no significant difference between the proportion of positive outcomes zzso zzso zzso zzso to zzso P zzso zzso in the zzso and intervention arms zzso rates, zzso zzso of zzso and zzso zzso of zzso zzso type zzso v zzso was not a predictor of zzso There was almost twice the zzso of adverse events worse than baseline in the zzso group after day 1 zzso rate ratio, zzso zzso zzso zzso to zzso P zzso zzso and throughout the zzso Those receiving zzso were more likely to experience a more severe grade of adverse event per day zzso ratio, zzso zzso zzso zzso to zzso P zzso zzso The number of patients needed to treat for one additional patient to have a positive outcome from zzso was 25 zzso zzso six to zzso The number needed to harm, because of zzso withdrawal, was six zzso zzso four to zzso 

zzso does not have net clinical benefit when used as an adjunct to zzso and standard zzso in cancer zzso 

